SPAG5 and triple-negative breast carcinoma: Viability assay further validated the oncogenic potential of SPAG5, which was counteracted either by miR-10b-3p overexpression or by SPAG5 depletion (Fig. 4I, J) in line with the results from SUM-159PT triple-negative breast cancer cell line (Supplementary Fig. 4H, I).